Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $285.98 million. The enterprise value is $540.38 million.
Important Dates
The last earnings date was Tuesday, February 11, 2025, after market close.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.85 million shares outstanding. The number of shares has decreased by -0.31% in one year.
| Current Share Class | 62.85M |
| Shares Outstanding | 62.85M |
| Shares Change (YoY) | -0.31% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 1.42% |
| Owned by Institutions (%) | 14.37% |
| Float | 31.94M |
Valuation Ratios
The trailing PE ratio is 197.77 and the forward PE ratio is 20.22. BIOX's PEG ratio is 1.69.
| PE Ratio | 197.77 |
| Forward PE | 20.22 |
| PS Ratio | 0.70 |
| Forward PS | 0.68 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 13.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.69 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 370.81 |
| EV / Sales | 1.33 |
| EV / EBITDA | 10.64 |
| EV / EBIT | 16.60 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.33 |
| Quick Ratio | 0.96 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | 5.63 |
| Debt / FCF | n/a |
| Interest Coverage | 1.21 |
Financial Efficiency
Return on equity (ROE) is 0.62% and return on invested capital (ROIC) is 3.38%.
| Return on Equity (ROE) | 0.62% |
| Return on Assets (ROA) | 2.46% |
| Return on Invested Capital (ROIC) | 3.38% |
| Return on Capital Employed (ROCE) | 5.96% |
| Revenue Per Employee | $1.05M |
| Profits Per Employee | $3,746 |
| Employee Count | 389 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.06 |
Taxes
| Income Tax | -6.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.19% in the last 52 weeks. The beta is 0.54, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -65.19% |
| 50-Day Moving Average | 6.32 |
| 200-Day Moving Average | 8.62 |
| Relative Strength Index (RSI) | 27.59 |
| Average Volume (20 Days) | 345,681 |
Short Selling Information
| Short Interest | 689,088 |
| Short Previous Month | 584,325 |
| Short % of Shares Out | 1.10% |
| Short % of Float | 2.16% |
| Short Ratio (days to cover) | 3.36 |
Income Statement
In the last 12 months, BIOX had revenue of $407.77 million and earned $1.46 million in profits. Earnings per share was $0.02.
| Revenue | 407.77M |
| Gross Profit | 169.50M |
| Operating Income | 32.55M |
| Pretax Income | 9.30M |
| Net Income | 1.46M |
| EBITDA | 50.77M |
| EBIT | 32.55M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $31.20 million in cash and $285.60 million in debt, giving a net cash position of -$254.40 million or -$4.05 per share.
| Cash & Cash Equivalents | 31.20M |
| Total Debt | 285.60M |
| Net Cash | -254.40M |
| Net Cash Per Share | -$4.05 |
| Equity (Book Value) | 346.00M |
| Book Value Per Share | 4.93 |
| Working Capital | 94.90M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 41.57%, with operating and profit margins of 7.98% and 0.36%.
| Gross Margin | 41.57% |
| Operating Margin | 7.98% |
| Pretax Margin | -1.07% |
| Profit Margin | 0.36% |
| EBITDA Margin | 12.45% |
| EBIT Margin | 7.98% |
| FCF Margin | n/a |